Market Overview

I think you’ll love what you hear,
what you’ll see and the opportunities
that will be set before you.
- Jon Najarian

Credit Suisse Downgrades United Therapeutics To Underperform


Analysts at Credit Suisse downgraded United Therapeutics (NASDAQ: UTHR) from Neutral to Underperform.

The price target for United Therapeutics has been raised from $100 to $120.

United Therapeutics shares have surged 44.98% over the past 52 weeks, while the S&P 500 index has gained 14.12% in the same period.

United Therapeutics' shares fell 2.51% to close at $131.42 yesterday.

Latest Ratings for UTHR

May 2019UpgradesSellNeutral
May 2019UpgradesUnderperformNeutral
May 2019MaintainsOutperformOutperform

View More Analyst Ratings for UTHR
View the Latest Analyst Ratings

Posted-In: Credit SuisseDowngrades Analyst Ratings


Related Articles (UTHR)

View Comments and Join the Discussion!

Latest Ratings

View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at

UPDATE: KBR Unveils Plan to Reorganize Into Three New Businesses

UPDATE: Credit Suisse Downgrades Ariad Pharmaceuticals As Launch Metrics Are Still Weak